Syntara Limited · ASX:SNT
Syntara — Investor Presentation (July 2024)
43 slides from Syntara's investor presentation, Jul 30, 2024
Slide 1: Equity Raising Presentation
For personal use only ™ Equity Raising Presentation Gary Phillips, CEO 30 July 2024 Not for release to US wire services or distribution in the United States
Slide 2: Disclaimer
Disclaimer Disclaimer This presentation has been prepared by, and is the sole responsibility of Syntara Limited ABN 75 082 811 630 (the Company or Syntara) and is dated 30 July 2024. The Company is under no obligation to update or keep the information represented in this presentation current past th
Slide 3: Disclaimer
Disclaimer Geographical restrictions The distribution of this presentation in jurisdictions outside Australia may be restricted by law. Please refer to the Foreign jurisdiction selling restrictions section of this presentation. This presentation may not be For personal use only released to US wire s
Slide 4: Who We Are
• Clinical stage drug development company with a pipeline of pre-clinical and clinical stage assets in fibrosis and inflammation Who We Are • Focused on first and best in class disease modifying drugs to improve quality of life and extend life expectancy • Prioritising haematological malignancies wi
Slide 5: Executive Summary
For personal use only Executive Summary
Slide 6: Syntara is the global leader in lysyl oxidase chemistry and biology
Syntara is the global leader in lysyl oxidase chemistry and biology Multi year research program leveraged with extensive scientific collaborations worldwide has delivered For personal use only three drugs now in phase 1c/2 studies Lysyl oxidases mediate the final stage in fibrosis SNT-5505 in Oncolo
Slide 7: Preclinical science and collaborations validated in high impact publications
Preclinical science and collaborations validated in high impact publications. For personal use only Myelofibrosis • Treatment with lysyl oxidase inhibitor significantly reduced reticulin fibrosis and megakaryocyte cell number in GATA-1low mice and JAK2V617F female mice Pancreatic Cancer • SNT-5505 a
Slide 8: Potential to deliver near term value
Potential to deliver near term value Pipeline creates multiple opportunities in high value markets For personal use only Anticipated Upcoming Addressable market Drug Candidate Indication Phase Milestones (US$) Interim 6 month data Myelofibrosis Phase 2 ~$1 billion1 December 2024 SNT-5505 Myelodyspla
Slide 9: Recent & anticipated news flow
Recent & anticipated news flow Strong and growing pipeline with advancement in studies expected to provide value inflection points For personal use only COMPLETED COMPLETED COMPLETED Q3 2024 Q3 2024 Q4 2023 Q4 2023 Q4 2023 SNT-4728 iRBD / SNT-5505 Phase 2a SNT-5505 Phase 2a SNT-5505 Phase 2a Syntara
Slide 10: Evolution from Pharmaxis to Syntara: Cost savings and clear clinical focus
Evolution from Pharmaxis to Syntara1: Cost savings and clear clinical focus For personal use only The main factors impacting cash from separation of the mannitol business unit (MBU) are: Proforma Cash Expenses 20232 • Employee numbers dropped from ~67 to ~26 FTEs 35,000 • Much reduced space requirem
Slide 11: Syntara Board under new leadership and downsized
Syntara Board under new leadership and downsized Significant international pharmaceutical experience For personal use only Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice President • Exp
Slide 12: Experienced senior management team
Experienced senior management team Significant global experience in drug development, commercialisation and partnering Scientific excellence Gary Phillips Jana Baskar • Global leaders in amine oxidase chemistry Chief Executive Officer Chief Medical Officer and biology – key to For personal use only
Slide 13: Terms of sale of MBU to Arna Pharma (acquiror)
Terms of sale of MBU to Arna Pharma (acquiror) Key terms of sale For personal use only ▪ Sale completed 18 October 2023. Business sale agreement amended effective 31 January 2024 ▪ Transition period (18 October 2023 to 31 January 2024) o SNT retained facility lease and MBU employees to support the m
Slide 14: Sale of Mannitol Business Unit to Arna Pharma
Sale of Mannitol Business Unit to Arna Pharma Current status For personal use only • After amounts already paid by the • Acquiror has recently challenged acquiror (~$2.5m), the amounts currently amounts claimed by SNT primarily claimed by SNT at 30 June 2024 are: related to the fixed payments • Fixe
Slide 15: Equity Raising
For personal use only Equity Raising
Slide 16: Equity Raising Summary
Equity Raising Summary • The Offer: $5.0m two tranche placement (Placement) comprising the issue of 178.6 million new fully paid For personal use only ordinary shares (New Shares): - Tranche 1 to raise approximately A$2.7m within the Company’s existing placement capacity under ASX Listing Rule 7.1;
Slide 17: Sources and Use of Funds
Sources and Use of Funds Anticipated Sources of Funds1, 2 Existing cash as at 30 June 2024 A$m $3.5 Funds including proceeds raised under the Placement will be used to fund: R&D tax credits (FY24) $3.6 For personal use only Cash from returned security deposits and sale of assets $0.9 MF combination
Slide 18: Indicative Timetable
Indicative Timetable Event Time (AEST) / Date For personal use only Announce completion of Placement, trading halt lifted and recommencement of trading Tuesday, 30 July 2024 Settlement of Tranche 1 Monday, 5 August 2024 Tranche 1 New Shares commence normal trading Tuesday, 6 August 2024 GM to approv
Slide 19: Program Update
For personal use only Program Update
Slide 20: Myelofibrosis (MF)
For personal use only Myelofibrosis (MF) Not for release to US wire services or distribution in the United States
Slide 21: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells For personal use only Key Facts Primary Myelofibrosis is Current standard SNT-5505 characterised by a build up of scar of care (SoC): JAK inhibition In contrast to SoC tissue (fibrosis) in bone
Slide 22: SNT-5505 Phase 2a trial part 1; Monotherapy in JAK inhibitor treatment failures
SNT-5505 Phase 2a trial part 1; Monotherapy in JAK inhibitor treatment failures Demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity For personal use only Study Design Endpoints Trial Outlooks • IND approved Q3 2020 • SNT-5505 has been well •
Slide 23: Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor
Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor Fastest route to meaningful data with no dose escalation and utilising existing trial infrastructure Study Plan For personal use only • 19 clinical trial sites Treatment Cohort Design Endpoints • Recruitment started 13 Dec 2023 I
Slide 24: Strong interest in myelofibrosis assets from strategics
Strong interest in myelofibrosis assets from strategics Target / Acquiror / / For personal use only Date of Feb-2024 June-2023 July-2022 Announcement Drug Name Pelabresib Pacritinib Momelotinib Lead Indication / Myelofibrosis Myelofibrosis Myelofibrosis Phase (Successful Phase 3 (Marketed) (FDA File
Slide 25: Myelodysplastic Syndromes (MDS)
For personal use only Myelodysplastic Syndromes (MDS) Not for release to US wire services or distribution in the United States
Slide 26: Myelodysplastic syndrome (MDS) is a blood cancer
Myelodysplastic syndrome (MDS) is a blood cancer Diverse bone marrow disorders characterized by inadequate production of healthy blood cells Key Facts 12–20k new cases are reported every Treatment of MDS For personal use only year in the US (87k p.a. worldwide) Current standard of care: Hypomethylat
Slide 27: Phase 1c/2a study in low and intermediate risk MDS
Phase 1c/2a study in low and intermediate risk MDS Study organisation Grant funded Australian investigator study with specialist CRO to deliver first results by mid 2025 • $0.83m grant from the For personal use only Australian Medical Research Future Fund (MRFF). Study Study Design Treatment Endpoin
Slide 28: Phase 1c/2a study in high-risk MDS/CMML study
Phase 1c/2a study in high-risk MDS/CMML study German investigator study with specialist CRO – Grant Pending Study organisation For personal use only • Grant pending • Syntara to provide free drug supply Study Design Treatment Endpoints • Clinical trial protocol Population Cohort received a top ratin
Slide 29: Skin Scarring
For personal use only Skin Scarring Not for release to US wire services or distribution in the United States
Slide 30: Hypertrophic and keloid scarring
Hypertrophic and keloid scarring Cutaneous scarring following skin trauma or a wound is a major cause of morbidity and disfigurement For personal use only Key Facts • Mechanisms underlying scar • Pre clinical evidence formation are not well established; prophylactic and - Treatment with SNT-6302 100
Slide 31: SNT-6302 phase 1c Trial in established skin scars (Solaria); Top line results
SNT-6302 phase 1c Trial in established skin scars (Solaria 2); Top line results For personal use only SNT-6302 well tolerated Mean inhibition of LOX Meaningful changes in the Longer study required to and demonstrated a activity 66% compared to composition of the scars show appearance and good safety
Slide 32: Syntara skin scarring clinical development plan
Syntara skin scarring clinical development plan For personal use only Incidences of skin rash Unprecedented Scar prevention with Collaboration with SNT-6302 in structural changes oral pan-LOX with Professor Solaria trial suggest effected by 3 months inhibitor progressing Fiona Wood and potential dev
Slide 33: APPENDIX
For personal use only APPENDIX
Slide 34: Risks
Risks The Company’s business is subject to a number of significant risks and uncertainties both specific to its business and of a general nature, some of which are summarised below. For personal use only As such, potential investors should be aware that investing in the Company’s securities involves
Slide 35: Key business risks
Key business risks (a) Overview The Company’ business success is currently substantially dependent on its ability to successfully advance the clinical development of SNT-5505, SNT-6302 (and For personal use only related back up compounds) and SNT-4728 in a timely manner. There is a risk that the cli
Slide 36: Key business risks
Key business risks (c) The time and cost to undertake clinical trials and obtain regulatory approval may be significantly more than expected The length of time and the cost necessary to complete clinical trials and to submit an application for marketing approval may vary significantly based on the t
Slide 37: Key business risks
Key business risks (e) The Company may not be successful in developing or securing new product candidates Although the Company already has an extensive product candidate pipeline, it continues to spend limited resources developing new product candidates. From time to time it also considers in-licens
Slide 38: Key business risks
Key business risks h) Mannitol business unit In October 2023, the Company sold its mannitol business unit. The acquiror has challenged certain amounts claimed by the Company under the sale agreement. The Company has appointed external counsel to actively pursue legal remedies to recover those amount
Slide 39: Key business risks
Key business risks (k) Even if a product is approved, the product may not warrant launch or even if launched, may not be successful in the market There is a risk that the product candidates the Company is developing and future product candidates, even if they receive regulatory approval may not gain
Slide 40: Key business risks
Key business risks (p) Patents and trade secrets The Company uses patents or trade secrets to protect its technologies from unauthorised use by third parties. The term of patents may expire or may be For personal use only challenged, invalidated or circumvented. There can be no assurances that the C
Slide 41: Foreign jurisdiction selling restrictions
Foreign jurisdiction selling restrictions This document does not constitute an offer of new ordinary shares (New Shares) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold,
Slide 42: Foreign jurisdiction selling restrictions
Foreign jurisdiction selling restrictions Singapore This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in For personal use only Singapore with the Monetary Authority of Singapore. Accordingly, this document and any ot
Slide 43: Contact details
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au David McGarvey Chief Financial Officer david.mcgarvey@syntaraTX.com.au www.syntaraTX.com.au